The present disclosure relates to the field of synthetic pharmaceutical chemistry and biology. The disclosure provides a compound of Formula I and a process of preparation thereof. The disclosure further relates to methods and use of Formula I compounds as stimuli-responsive probes. Said Formula I compounds are employed for detecting and quantifying reactive oxygen species (ROS), and have related applications including but not limited fluorescence spectroscopy, diagnostics, treatment, imaging and biomedical applications. ##STR00001##

A bioelectrochemical sensor utilizing a nanoporous gold electrode. The bioelectrochemical sensor is suitable for measuring redox in biologic media while having increased resistance to biofouling as compared to conventional electrodes such as planar gold electrodes, due to greater exposed surface area of the three-dimensional ligature structure defining the nanopores. The nanopores have a pore size of 5-100 nm, preferably with an average pore size of less than 50 nm, and more preferably with an average pore size of less than 20 nm.

The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.

The aspects of the disclosed embodiments relate to method for determining a likelihood of an inflammatory gastrointestinal tract disease. The method includes diluting a biological sample of a human subject and contacting it with 8-anilinonaphthalene-1-sulfonic acid as modulating agent and further with a reagent, said reagent comprising a peroxidase enzyme and a label selected from a europium chloride and terbium chloride. The sample is incubated and excited, and the time-resolved luminescence signal of the label in the sample is measured. If the luminescence signal is at least 112% higher than for a control sample from a human so subject without of an inflammatory intestine disease, an increased likelihood of an inflammatory intestine disease of the human subject is determined.

The present invention relates to a method of evaluating neutrophil activity, which includes: evaluating neutrophil activity based on an index derived from measurement results of myeloperoxidase (MPO) activity or superoxide production of a biological sample to which a neutrophil stimulant is added, in which the index is a time from addition of the neutrophil stimulant to rise of a peak of the MPO activity or the superoxide production.

The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.

Methods are provided that allow global access to redox-based molecular information by coupling electrochemical measurements with signal processing approaches. More specifically, the disclosure provides methods that rely on the use of redox probes to assay samples for redox activities that act to exchange electrons with the probe thereby generating detectable optical and electrochemical signature signals that can then be assigned to a sample feature of interest. In particular embodiments, the disclosed assay methods are useful for diagnosis and prognosis of disorders, such as schizophrenia, that are found to be associated with a specific redox-based signature within a subject sample.

The present invention relates to a benzene ring compound and a use thereof. In particular, provided is a compound as shown in formula I, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof. The present compound has good therapeutic effects on tumors

##STR00001##

A bioelectrochemical sensor utilizing a nanoporous gold electrode. The bioelectrochemical sensor is suitable for measuring redox in biologic media while having increased resistance to biofouling as compared to conventional electrodes such as planar gold electrodes, due to greater exposed surface area of the three-dimentional ligature structure defining the nanopores. The nanopores have a pore size of 5-100 nm, preferably with an average pore size of less than 50 nm, and more preferably with an average pore size of less than 20 nm.

Provided is, as an attempt to realize a method for measuring oxidative stress in human body fluids, a means for measuring reactive oxygen species containing a color indicator that detects the amount of reactive oxygen species present in the human body by causing a color change through reaction with malondialdehyde present in the urine or blood. The detection means has advantages of detecting malondialdehyde (MDA) present at a low concentration in a sample (urine or blood) and exhibiting excellent discrimination owing to high detection sensitivity.